194 related articles for article (PubMed ID: 9408695)
21. The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir.
Brennan DC; Storch GA; Singer GG; Lee L; Rueda J; Schnitzler MA
J Infect Dis; 2000 May; 181(5):1557-61. PubMed ID: 10823753
[TBL] [Abstract][Full Text] [Related]
22. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group.
Frenkel LM; Capparelli EV; Dankner WM; Xu J; Smith IL; Ballow A; Culnane M; Read JS; Thompson M; Mohan KM; Shaver A; Robinson CA; Stempien MJ; Burchett SK; Melvin AJ; Borkowsky W; Petru A; Kovacs A; Yogev R; Goldsmith J; McFarland EJ; Spector SA
J Infect Dis; 2000 Dec; 182(6):1616-24. PubMed ID: 11069232
[TBL] [Abstract][Full Text] [Related]
23. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection.
Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M
Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
[TBL] [Abstract][Full Text] [Related]
25. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
[TBL] [Abstract][Full Text] [Related]
26. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
Ruttmann E; Geltner C; Bucher B; Ulmer H; Höfer D; Hangler HB; Semsroth S; Margreiter R; Laufer G; Müller LC
Transplantation; 2006 May; 81(10):1415-20. PubMed ID: 16732179
[TBL] [Abstract][Full Text] [Related]
27. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus involving gastrointestinal tract in renal transplant recipients.
Shrestha BM; Parton D; Gray A; Shephard D; Griffith D; Westmoreland D; Griffin P; Lord R; Salaman JR; Moore RH
Clin Transplant; 1996 Apr; 10(2):170-5. PubMed ID: 8664513
[TBL] [Abstract][Full Text] [Related]
29. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
Reischig T; Opatrný K; Treska V; Mares J; Jindra P; Svecová M
Kidney Blood Press Res; 2005; 28(4):218-25. PubMed ID: 16043964
[TBL] [Abstract][Full Text] [Related]
30. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.
Turgeon N; Fishman JA; Doran M; Basgoz N; Tolkoff-Rubin NE; Cosimi AB; Rubin RH
Transpl Infect Dis; 2000 Mar; 2(1):2-10. PubMed ID: 11429003
[TBL] [Abstract][Full Text] [Related]
31. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients.
Pescovitz MD
Transpl Infect Dis; 1999; 1 Suppl 1():31-4. PubMed ID: 11565585
[TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of ganciclovir in pediatric renal transplant recipients.
Zhang D; Lapeyraque AL; Popon M; Loirat C; Jacqz-Aigrain E
Pediatr Nephrol; 2003 Sep; 18(9):943-8. PubMed ID: 12883977
[TBL] [Abstract][Full Text] [Related]
34. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children.
Green M; Kaufmann M; Wilson J; Reyes J
Clin Infect Dis; 1997 Dec; 25(6):1344-9. PubMed ID: 9431375
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
[TBL] [Abstract][Full Text] [Related]
36. Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients.
Villeneuve D; Brothers A; Harvey E; Kemna M; Law Y; Nemeth T; Gantt S
Pediatr Transplant; 2013 Feb; 17(1):80-5. PubMed ID: 23240598
[TBL] [Abstract][Full Text] [Related]
37. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients.
Ginevri F; Losurdo G; Fontana I; Rabagliati AM; Bonatto L; Valente R; Venzano P; Nocera A; Basile GC; Valente U; Gusmano R
Transpl Int; 1998; 11 Suppl 1():S130-4. PubMed ID: 9664962
[TBL] [Abstract][Full Text] [Related]
38. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients.
Vaudry W; Ettenger R; Jara P; Varela-Fascinetto G; Bouw MR; Ives J; Walker R;
Am J Transplant; 2009 Mar; 9(3):636-43. PubMed ID: 19260840
[TBL] [Abstract][Full Text] [Related]
39. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.
Winston DJ; Wirin D; Shaked A; Busuttil RW
Lancet; 1995 Jul; 346(8967):69-74. PubMed ID: 7603215
[TBL] [Abstract][Full Text] [Related]
40. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.
Yu MA; Park JM
Expert Opin Pharmacother; 2013 Apr; 14(6):807-15. PubMed ID: 23469871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
